Literature DB >> 25497265

Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment.

Alexander T Cohen1, Robert Harrington2, Samuel Z Goldhaber3, Russell Hull4, C M Gibson5, Adrian F Hernandez6, Alex Gold7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25497265     DOI： 10.1016/j.ahj.2014.09.004

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  4 in total

1.  Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients?

Authors:  Franco Piovella; Diana Irina Iosub
Journal:  Intern Emerg Med       Date:  2018-09-27       Impact factor: 3.397

Review 2.  Betrixaban for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients: Putting the APEX Results into Practice.

Authors:  Kayla M Miller; Michael J Brenner
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 3.  Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism.

Authors:  Noel C Chan; Vinai Bhagirath; John W Eikelboom
Journal:  Vasc Health Risk Manag       Date:  2015-06-26

4.  Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers.

Authors:  Scott C Woller; Scott M Stevens; Masarret Fazili; James F Lloyd; Emily L Wilson; Gregory L Snow; Joseph R Bledsoe; Benjamin D Horne
Journal:  Res Pract Thromb Haemost       Date:  2021-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.